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Abstract 1 
Human induced pluripotent stem cells (hiPSCs) represent an ideal in vitro platform to study 2 
human genetics and biology. The recent advent of programmable nucleases makes also the 3 
human genome amenable to experimental genetics through either the correction of 4 
mutations in patient-derived iPSC lines or the de novo introduction of mutations into 5 
otherwise healthy iPSCs. The production of specific and sometimes complex genotypes in 6 
multiple cell lines requires efficient and streamlined gene editing technologies. In this article 7 
we provide protocols for gene editing in hiPSCs. We presently achieve high rates of gene 8 
editing at up to three loci using a modified iCRISPR system. This system includes a 9 
doxycycline inducible Cas9 and sgRNA/reporter plasmids for the enrichment of transfected 10 
cells by fluorescence-activated cell sorting (FACS). Here we cover the selection of target 11 
sites, vector construction, transfection, and isolation and genotyping of modified hiPSC 12 
clones. 13 
 14 
1. Introduction 15 
Human induced pluripotent stem cells (hiPSCs) represent an ideal platform to study human 16 
genetics and biology in vitro [1,2]. Induced pluripotent stem cell lines can be established by 17 
reprogramming of somatic cells from any healthy or diseased individual [3], being able to 18 
embody the diversity of genotypes within the human population. Since hiPSCs are self-19 
renewing they can be propagated indefinitely in the pluripotent state but on demand 20 
differentiated into selected cell types such as neurons [4] or cardiomyocytes [5]. 21 
The strength of non-human model organisms is based on in vivo analysis and the availability 22 
of reverse and forward genetic tools enabling functional genomics studies which unravel 23 
genotype to phenotype connections, including disease related variants. The recent advent of 24 
programmable nucleases makes also the human genome amenable to experimental 25 
genetics through either the correction of mutations in patient-derived iPSC lines or the de 26 
novo introduction of mutations into otherwise healthy iPSCs [6,7]. Some heritable diseases 27 
are strictly monogenetic, but observable phenotypes often depend on epistatic interaction 28 
from multiple genes. An understanding of disease-specific epistasis will improve the 29 
prediction of disease risks and elucidate disease mechanisms, e.g. distinguishing between 30 
disease specifiers and modifiers [8,9]. In animal genetics genotypes and backgrounds can be 31 
constructed and manipulated by breeding and backcrossing. In hiPSCs the genome is fixed, 32 
so studies investigating the effects of human genetic diversity require the use of multiple cell 33 
lines side-by-side.  34 
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The production of specific and sometimes complex genotypes in multiple cell lines requires 35 
efficient and streamlined gene editing technologies. We presently achieve high rates of gene 36 
editing at up to three loci using a modified iCRISPR system. This system includes a 37 
doxycycline inducible Cas9 and sgRNA/reporter plasmids for the enrichment of transfected 38 
cells by fluorescence-activated cell sorting (FACS). In this article we provide our protocols for 39 
gene editing in hiPSCs. Here we cover the selection of target sites, vector construction, 40 
transfection, and isolation and genotyping of modified hiPSC clones. 41 
 42 
1.1 Gene editing in hiPSCs 43 
Due to its efficiency and simplicity, the CRISPR/Cas9 system derived from Streptococcus 44 
pyogenes [10] has  become  the preferred method for gene editing in mammalian cells [11–45 
13]. CRISPR/Cas9 gene editing requires two basic components to achieve a DNA double-46 
strand break (DSB) and subsequent gene editing: the Cas9 nuclease protein and a single 47 
guide (sg)RNA to home the Cas9 nuclease. A DNA repair template is often additionally 48 
provided to allow for homology directed repair (HDR). The first twenty nucleotides of sgRNAs 49 
direct Cas9 to a specified complementary DNA target sequence via RNA-DNA hybridization. 50 
The target sequence is always located upstream of an invariant protospacer adjacent motif 51 
(PAM) sequence (NGG for SpCas9 from Streptococcus pyogenes). Upon correct 52 
hybridization the Cas9 nuclease undergoes a conformational change and creates a DSB 53 
located 3 bp upstream of the PAM site (Fig.1A, B) [14]. An advantage of the CRISPR/Cas9 54 
system is that the Cas9 protein component is of universal use and new target sites can be 55 
easily targeted by addition of a new sgRNA sequence. The gene editing process follows 56 
induction of DSBs where DNA repair pathways result in deletion, replacement or insertion of 57 
sequences. 58 
Two main DNA repair pathways exist in mammalian cells. In most instances DSBs 59 
are repaired by the non-homologous end joining (NHEJ) pathway. NHEJ religates open DNA 60 
ends using DNA ligase IV without using a repair template [15]. DSBs processed by the NHEJ 61 
pathway frequently exhibit random small deletions and/or insertions of nucleotides (indels) 62 
(Fig. 1C). Within coding regions this results in frameshift (knockout) mutations in the majority 63 
of cases. Alternative to NHEJ, DSBs can be repaired by HDR and requires a DNA molecule 64 
as repair template [16,17]. The natural endogenous use of HDR is for spontaneously 65 
occurring DSBs. Cycling cells use the intact homologous region of the sister chromatid as 66 
HDR template. To achieve precise sequence modifications at targeted DSBs, the HDR 67 
pathway can be exploited to copy in a sequence of interest. This is done through the addition 68 
of an artificial DNA template which mimics the sister chromatid by including homology 69 
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sequences located up- and downstream of the DSB and concurrently flanking a desired 70 
sequence modification or insertion [18]. In the repair process gene conversion extends from 71 
the template`s homology regions into the heterologous sequence and also transfers the 72 
modified region into the target sequence (knockin), enabling to introduce precise mutations 73 
such as codon replacements or the insertion of reporter genes (Fig. 1C). Large sequence 74 
insertions require the construction of plasmid-based gene targeting vectors which include 75 
homology regions of > 1000 bp, whereas small sequence modifications can be introduced by 76 
using synthetic single-stranded DNA oligonucleotides (ssODN) with lengths of 100-150 nt. In 77 
cycling cells both repair mechanisms work side by side, but most DSBs are repaired by the 78 
prevailing NHEJ pathway whereas HDR occurs less frequently. In a population of transfected 79 
hiPSCs cells the induction of DSBs leads to a variety of repaired alleles in individual cells. 80 
Therefore, single cell-derived subclones are established from this heterogeneous population 81 
and genotyped for the presence of the desired mutant alleles. Isolated clones may harbor 82 
none, one or two differing mutant alleles and the occasional presence of non-clonal, mixed 83 
colonies make precise genotyping an elaborate task to exclude errors. Efficient mutagenesis 84 
protocols ensuring that gene editing occurs in the majority of treated cells are important to 85 
avoid the time-intensive expansion and genotyping of large numbers of unedited wildtype 86 
hiPSC clones. 87 
Sequence deletions leading to gene inactivation (knockout) are commonly used for 88 
modelling loss of function alleles. Sequence replacements aim for the introduction or 89 
correction of disease-related point mutations. Sequence insertions are often used for the 90 
generation of cell type-specific reporter alleles or the ectopic expression of therapeutic 91 
proteins [6,7]. Furthermore, the multiplex gene editing approach enables the simultaneous 92 
processing of several target genes by the combination of multiple sgRNAs [19]. 93 
Frequent gene editing applications include the correction of disease-related mutations 94 
in patient-derived hiPSCs. The resulting engineered hiPSCs differ from the parental cells 95 
exclusively at the edited loci and are otherwise isogenic. Parallel differentiation of these 96 
isogenic cell lines into disease-relevant cell-types provides the basis for the phenotypic 97 
analysis of cellular pathologies that are directly attributable to the genetic specific mutations 98 
[2,20,21]. This reversion of disease-related phenotypes in cells derived from corrected 99 
hiPSCs can serve as a paradigm for the feasibility of future cell based therapies. The 100 
CRISPR/Cas9 system can be used for modification of both copies of a target gene, or 101 
restricted to induce changes only in alleles of interest by selective gene editing based on 102 
haplotype-specific target sites [22–25].  103 
Gene editing in hiPSCs and other cells is now routinely performed using the 104 
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unmodified Cas9 nuclease. Effective use of Cas9 is constrained by the dependence on the 105 
invariant PAM (NGG) motif and imperfect selectivity resulting in cleavage of unintended 106 
genomic, `off-target´ sequences that exhibit one or more mismatches to the desired on-target 107 
site [26]. The level of off-target activity complicates Cas9 applications in cell-based disease 108 
modeling as well as in clinical translation. The off-target cleavage can be minimized by 109 
choosing target sequences showing minimal homology elsewhere in the genome. Whole 110 
genome sequencing of hiPSCs does not observe off-target effects if highly specific gRNAs 111 
are used [27–29]. Additionally, the specificity of Cas9 has been improved by engineering 112 
forms that destabilize the protein`s interaction with the DNA. By decreasing the strength of 113 
nonspecific DNA interactions through amino acid substitutions, the resulting Cas9 variants 114 
are thermodynamically more dependent on perfect gRNA-DNA pairings, leading to 115 
decreases in off-target binding and cleavage. Two of these enzymes have been produced.  116 
Zhang et al. [30] focused on residues that interact with the non-target DNA strand to 117 
generate `enhanced´ Cas9 (eCas9), whereas Joung [31] altered amino acids that contact the 118 
DNA backbone on the target strand obtaining `high-fidelity´ Cas9 (Cas9-HF). Using unbiased 119 
genome-wide assays, both groups showed greatly reduced off-target activity below 120 
detectable levels. The on-target cleavage of these variants is comparable (eCas9) or 121 
approaches (Cas9-HF) the activity of wild-type Cas9. These modified nucleases are not yet 122 
broadly used in hiPSCs but provide opportunities for future application. 123 
 124 
- Figure 1 - 125 
 126 
1.2 Human induced pluripotent stem cell lines 127 
hiPSC lines can be established either from healthy individuals or from patients with inherited 128 
or idiopathic diseases. Lines from healthy individuals either serve for studying human 129 
developmental processes or as a framework for introduction of de novo or patient-derived 130 
mutations into disease-associated genes. Patient-derived hiPSCs are used to study an 131 
individual disease-prone genotype and the role of mutations identified in disease-related 132 
genes. A large resource is the HipSci initiative [32] that offers more than 400 hiPSC lines 133 
(www.hipsci.org) which are distributed via the ECACC (www.phe-culturecollections.org.uk). 134 
Moreover, a variety of human stem cell lines is available from WiCell (www.wicell.org).  135 
Despite the importance of allelic variants as part of the genetic background, it is a shortfall of 136 
the present hiPSC research that genome sequences for most cell lines are not available, 137 
except for the HipSci resource which offers whole exome sequencing (WES) for all and 138 
whole genome sequencing (WGS) data for selected lines. Different hiPSC lines exhibit 139 
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individual properties such as susceptibility to various transfection treatments or culture 140 
techniques approaches (see section 3.3). 141 
1.3 Gene editing approach 142 
The purpose of gene editing in a hiPSCs workflow may be the insertion of a specific 143 
sequence from a HDR donor template, or the deletion of a genomic sequence. Templates for 144 
HDR-mediated knockin may use donor vectors that include drug selection or fluorescent 145 
marker genes enabling the efficient isolation of targeted colonies harboring stable vector 146 
integrations  [33,34]. In some cases, especially for gene therapeutic purposes, the marker 147 
gene needs to be removed. This can be achieved by flanking the marker gene with 148 
recombinase or transposase recognition sites that upon transient expression of recombinase 149 
or transposase facilitate the removal of the marker gene. Alternatively, templates without 150 
selection marker genes can be used for HDR such as ssODNs [35], providing that gene 151 
editing in the population of transfected cells is highly efficient. 152 
Efficient methods would ideally allow the simultaneous introduction of knockout or 153 
knockin mutations into multiple genes (multiplex engineering) in different cell lines with 154 
limited efforts. A first step into the direction of multiplexed gene editing is the genomic 155 
integration of an inducible Cas9 expression vector into the AAVS1 locus. This allows for the 156 
delivery of sgRNAs and HDR donors only, while yielding an increased gene targeting efficacy 157 
in hiPSC. This approach was first described in hiPSCs as the doxycycline inducible iCRISPR 158 
system which just requires the transfection of multiple sgRNAs and allows the knockout of up 159 
to three genes in a single step [19]. Depending on the experimental setup, both classical 160 
CRISPR/Cas9 and the iCRISPR system feature advantages and drawbacks. The former is 161 
applicable to wildtype cells if no further genomic modifications are desired, e.g. experimental 162 
(re-)engraftments. The latter was demonstrated to provide improved efficacy when applied to 163 
modify multiple loci, although prior cell line generation is required and a modified AAVS1 164 
locus will remain if no strategies for final Cas9 gene removal are applied. 165 
In this protocol we include two ways to achieve gene editing in hiPSCs. Both describe 166 
detailed procedures on how to introduce CRISPR/Cas9-mediated, site-specific DSBs 167 
followed by suggestions for analysis of resulting indel formations. These methods can further 168 
provide a framework for HDR-mediated insertion.  169 
The first approach, enables editing of single genes by transfection of a vector 170 
encoding Cas9 and sgRNA (cloned into pU6-(BbsI)sgRNA_CAG-Cas9-bpA_EF1-TagRFP or 171 
pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA, section 3.1.1) into unmodified hiPSC lines 172 
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(Workflow A, Fig. 2A). Included fluorescent Venus or RFP reporters enable subsequent 173 
FACS isolation of transfected cells. The second approach focuses on multiplex gene editing 174 
(Workflow B, Fig. 2B, 2C). This multiplexing protocol uses hiPSC lines with a doxycycline 175 
inducible Cas9 expression system integrated in the AAVS1 locus. We currently use a 176 
modified version of the iCRISPR system [19] which is available upon request. As described 177 
in section 3.3, these iCRISPR lines show a strong Cas9 expression when induced with 178 
doxycycline. These cells are transfected with a small vector for the expression a fluorescent 179 
Venus reporter and of multiple sgRNAs (cloned into plasmid pU6-(BbsI)sgRNA_CAG-Venus-180 
bpA; section 3.1.1). This allows the fraction of successfully transfected hiPSCs expressing 181 
sgRNAs and the reporter to be isolated by FACS. The sorted cells are then plated for the 182 
establishment of single cell derived colonies (section 3.4). 183 
Further improvements of this technology may be possible. We have found Cas9 to be 184 
heterogeneously expressed in iCRISPR cell lines after doxycycline induction. Therefore, we 185 
are further testing vectors for the induction of Cas9 and a second fluorescent reporter, 186 
enabling the two color FACS enrichment for cells expressing high levels of Cas9 and 187 
sgRNAs. 188 
 189 
- Figure 2 - 190 
 191 
1.4 Guide RNA selection and project planning 192 
The selection of an appropriate RNA target site is determined by the specific aim of each 193 
experiment. A frequent application of gene editing is the generation of knockout alleles by the 194 
induction of indel formation at the DSB site by error-prone NHEJ repair causing frameshift 195 
mutations and premature termination. To achieve gene disruption the sgRNA target site has 196 
to be located in a protein coding exon that is included in all splice variants. Despite the 197 
presence of a frameshift mutation in an mRNA, ribosomes may be able to reinitiate 198 
translation at an ATG codon located downstream, generating a shortened protein [36]. 199 
Therefore, coding regions should be analyzed for the likelihood of such illegitimate 200 
translation events using e.g. the Netstart prediction server 201 
(http://www.cbs.dtu.dk/services/NetStart/) [37]. Besides forming knock-outs by indel 202 
formation one can delete large sections of coding sequence or regulatory elements by cutting 203 
with two sgRNAs. Deletions not necessarily have to affect a gene itself, but can involve 204 
regulatory elements as well. Furthermore, chromosomal rearrangements, that are 205 
duplications and inversions of regions up to more than 1 Mb, can be generated by the use of 206 
two sgRNAs targeting sites in an appropriate distance [38,39]. 207 
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Once the genomic region of interest is identified a stretch of 150 – 250 bp can be 208 
analyzed for the distribution and quality of Cas9 target sites. Due to their simple structure 209 
target sites are found on average every 8–12 bp in the human genome and can be seen by 210 
visual inspection for NGG PAM motifs. However, the sequence composition of the 20 nt 211 
target sequence (such as GC content) influences the nuclease activity of Cas9 at the target 212 
site (on-target activity), as well as the probability that Cas9 cuts other related sites within the 213 
genome (off-target activity). To analyze all sgRNAs for their on-target efficiency and off-target 214 
sites we prefer to use the CRISPOR website (http://crispor.tefor.net/) [40]. CRISPOR 215 
provides scores for the specificity of sgRNAs as well as on-target efficiency using meta-216 
analysis of all published activity ranking tools. Various studies suggest that off-target sites of 217 
RNA-guided Cas9 nucleases can be variable in frequency, challenging to predict and it is not 218 
possible to predict how many mismatches can be tolerated [26]. Nevertheless, a careful 219 
selection among the target sequences addressing a given genomic region of interest will 220 
reduce the risk of creating off-target mutations. Therefore, we recommend to use only 221 
sgRNAs showing the highest specificity scores and to save the information on potential off-222 
target sites for later PCR analysis (see section 3.5.8).  223 
Genetic editing resulting in the generation of a knockin, being either an insertion or a regional 224 
replacement, is achieved by HDR. To generate such a targeted sequence modification, the 225 
sgRNA target site should be located close (< 100 bp) to the position of the intended mutation 226 
as the frequency of sequence conversion by HDR decreases with distance. Targeted 227 
mutations by HDR are guided by repair templates, being either ssODNs or plasmid gene 228 
targeting vectors [14,41]. ssODNs are convenient as they are synthetized for a reasonable 229 
price so that cloning work is not required. ssODNs used as HDR template contain a short 230 
sequence modification (deletion, insertion or substitution) flanked by two homology 231 
sequences. Many manufacturers of custom ssODNs offer lengths up to 150 nt or more, 232 
enabling the insertion of sequences of up to ~50 nt. When using ssODNs we recommend the 233 
selection of target sites that are less than 10 bp distant to the planned mutation. In the 234 
standard design, as their length is limited, a desired mutation is located at the center of an 235 
ssODN, resulting in similarly-sized homology regions (usually 40-60 nt each) that flank the 236 
desired mutation symmetrically on both sides. It is crucial to avoid the recognition and 237 
recleaving of the recombined allele by Cas9 by the inclusion of one or more silent nucleotide 238 
replacements to destroy the PAM recognition site. Silent mutations can be added to facilitate 239 
later screening for successful recombination, e.g. by the introduction of a recognition site for 240 
restriction enzymes for restriction fragment length polymorphism (RFLP).  241 
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Recent studies suggest that choice of the target strand and an asymmetric design of 242 
ssODNs increase the knockin efficiency [42] and that phosphorothioate (PTO) modifications 243 
improve stability and HDR efficacy [43]. However, it was not shown if these rules apply to 244 
hiPSCs as well. We have performed a side by side evaluation of ssODNs with symmetric or 245 
asymmetric structure with or without PTO modifications (Fig. 3). Analogously to Glaser et al. 246 
[44], we used human iPS cells heterozygously expressing a CAG promoter driven EGFP 247 
from the AAVS1 locus as a reporter system for HDR. The EGFP gene was targeted with a 248 
sgRNA to induce a DSB. By homologous recombination of donor templates that substitute 4 249 
bp, the original green fluorescent EGFP is converted to blue fluorescent BFP and the PAM 250 
sequence rendered non-functional, as previously reported [44]. Based on this assay, we 251 
observed that in hiPSCs unmodified ssODNs without PTO modifications yield higher HDR 252 
rates compared to modified ones (Fig. 3). Furthermore, in contrast to HEK293 cells as 253 
reported by Richardson et al. [42], a symmetric architecture of ssODNs resulted in higher 254 
HDR efficiencies than an asymmetrical in hiPSCs (Fig. 3). However, the efficacy of 255 
CRISPR/Cas9 mediated targeting of specific loci depends on the cell line subjected, the 256 
localization of the locus within the chromatin architecture and the sequence itself. Therefore, 257 
these observations cannot be generalized, but may vary in respect to the individual purpose. 258 
- Figure 3- 259 
For larger and more sophisticated modifications such as the insertion of cDNAs or 260 
reporter cassettes, targeting vectors with long homology arms are required. Such vectors 261 
include the insertion in between two regions homologous to sequences located up- and 262 
downstream of the DSB. For the design and construction of gene targeting vectors, adhere to 263 
protocols developed for gene targeting in mouse embryonic stem cells [45,46] with two 264 
exceptions: a drug selection cassette is not required and the homology arms used are often 265 
shorter (> 500 bp) that facilitates cloning by PCR or gene synthesis. For vector construction, 266 
homology arms can be PCR-amplified from isogenic genomic DNA and ligated into a cloning 267 
plasmid backbone. Alternatively, the insert can be generated by gene synthesis purchased 268 
from a commercial provider. In the simplest configuration the selected Cas9 recognition 269 
sequence should cover the region of the intended mutation, bridging the homology arms of 270 
the targeting vector to prevent its cleaving by Cas9, being specific only to the wildtype 271 
genomic DNA. 272 
 273 
1.5 Workflow of CRISPR/Cas9 gene editing in hiPSCs 274 
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For designing a new experimental setup our workflow for gene editing and clonal isolation of 275 
hiPSCs follows a generalized sequence, as shown in Figure 4: 1. Cloning of a suitable 276 
sgRNA expression vector. Assuming usage of available combined vectors to express Cas9 277 
and sgRNA (section 2., Vectors) 7 days are estimated for the procedure and quality control. 278 
2. Transfection of fluorescent reporter vectors carrying sgRNAs and Cas9 (Workflow A) or - if 279 
using an inducible Cas9 harboring iPS cell line - transfection with fluorescent reporter vectors 280 
carrying only sgRNAs (Workflow B) and if desired repair templates. 3. On day 9, 48 h post 281 
transfection, the successfully transfected cells are enriched by FACS sorting for the 282 
fluorescent reporter. 4. The FACS sorted cells are then plated at low density. To achieve a 283 
good viability in feeder-free conditions and to prevent spontaneous differentiation the cells 284 
are cultivated for 7 days in 50 % of conditioned medium [47]. 5. The single cell derived 285 
colonies can be picked on around day 16, further cultured and split to two separate 286 
cultivations each. 6. After expansion for 5 more days, one of the two cultivations is subjected 287 
to analysis of gene editing events (Fig. 6, B1-B6). 7. The other cultivation is kept in culture 288 
until establishment of the final cell line or preparation of cryopreserved stocks on day 28. 289 
Following these workflows and picking 24 colonies for further processing should yield at least 290 
two positive clone on average. However, as CRISPR/Cas9-mediated gene editing depends 291 
on the targeted loci as well as on the cell line used efficacies may vary. To promote 292 
increased efficacy of gene editing, we suggest performing a second round of transfection and 293 
FACS enrichment, and optionally to co-transfect a vector encoding for Trex2, an end-294 
processing enzyme.  295 
 296 
 297 
- Figure 4- 298 
2. Materials 299 
2.1 Vectors 300 
Workflow A 301 
- pU6-(BbsI)sgRNA_CAG-Cas9-bpA_EF1-TagRFP (Addgene ID 86987, 302 
www.addgene.org) or  303 
-pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA (Addgene ID 86986) 304 
Plasmids for the cloning of a single sgRNA into the BbsI site and separate the 305 
expression of Cas9 and RFP or the expression of a Cas9-venus fusion protein. 306 
 307 
Workflow B 308 
12 
 
- pU6-(BbsI)sgRNA_CAG-venus-bpA (Addgene ID 86985) 309 
Plasmid for the cloning of single or multiple sgRNAs into the BbsI site and the      310 
expression of Venus. 311 
 312 
Optional: Co-expression of Trex2 (pCAG-mTrex2-bpA; Addgene ID 86984) enhances indel 313 
formation. 314 
 315 
2.2 Cloning sgRNAs 316 
1. Empty sgRNA cloning vectors (section 2.1) 317 
2. A pair of target specific sgRNA oligos with BbsI overhangs, e.g. MWG-Biotech 318 
3. BbsI restriction enzyme, NEB, #R0539S 319 
4. AscI restriction enzyme, NEB, #R0558S 320 
5. T4 Ligase, NEB, #M0202S 321 
6. PureYield™ Plasmid Miniprep System, Promega, #A1222 322 
7. Chemical competent E. coli DH5α, Thermo Fisher, #18265-017 323 
8. Carbenicillin, Sigma, #C3416 324 
9. LB medium and LB agar plates 325 
10. Agarose gel electrophoresis (setup and consumables) 326 
 327 
2.3 General hiPS cell culture 328 
1. hiPS cell lines (e.g. HPSI0114i-kolf_2, www.hipsci.org or MIRJT7i-mND2-0, 329 
www.wicell.org) 330 
2. Essential 8 medium, Thermo Fisher Scientific, # A1517001 331 
3. Y-27632 (dihydrochloride), Biomol, # Cay10005583-5 332 
4. DPBS -/- (-Ca2+, -Mg2+), Life Technologies, # 14190169 333 
5. Vitronectin (VTN-N) Recombinant Human, Life Technologies, #  A14700 334 
6. Matrigel Matrix, Fisher Scientific, # 10162371 335 
7. DMEM/F-12 Hepes, Life Technologies, # 31330038  336 
8. Cell culture plates (e.g. Corning Costar 6-well plates, # CLS3516-50EA) 337 
9. Accutase solution, Sigma-Aldrich, # A6964 338 
10. Bambanker Serum Free Cell Freezing Medium, BioCat, # BB01-NP 339 
11. DMSO, Sigma-Aldrich, # D5879 340 
12. Doxycycline Hydrochloride, Sigma-Aldrich, # D9891 341 
13. Dissociation buffer: 0.18 % NaCl, 0.5 mM EDTA in DPBS (to 491.92 ml DPBS add 5 342 
ml of 0.5M EDTA pH 8.0 and 3.8 ml of 5M NaCl) 343 
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14. ReLeSR, Stemcell Technologies, # 05872 344 
 345 
2.4 Lipofection of hiPS cells 346 
1. Lipofectamine 3000 transfection kit, Life Technologies, # L3000001 347 
2. Opti-MEM I reduced serum medium, Gibco, # 31985062 348 
 349 
2.5 Electroporation of hiPS cells with the Neon system 350 
1. Neon Transfection system, Thermo Fisher Scientific, #  MPK5000 351 
2. Neon transfection kit 100µl, Thermo Fisher Scientific, # MPK10025 352 
 353 
2.6 Electroporation of hiPS cells with the Gene Pulser system 354 
1. Gene Pulser Xcell Electroporation Systems, Bio-Rad, # 1652660 355 
2. Gene Pulser electroporation cuvette 0.4 cm, Bio-Rad, # 1652081 356 
 357 
2.7 FACS enrichment of transfected hiPS cells 358 
1. 0.45 µm PTFE membrane filter, Millipore, # SLCR025NS 359 
2. FACS tubes with 35 µm strainer cap, Falcon, # 352235 360 
3. Penicillin/Streptomycin (10,000 U/ml), Life Technologies, # 15140122 361 
4. Gentamicin (10 mg/mL), Life Technologies, # 15710049 362 
5. RevitaCell Supplement (100X), Life Technologies, # A26445-01 363 
6. Fluorescence activated cell sorter (e.g. BD FACSAria III, BD Biosciences) 364 
 365 
2.8 Analyzing modifications 366 
1. Wizard Genomic DNA Purification Kit, Promega, # A1125 367 
2. Wizard DNA Clean-Up System, Promega, # A9282 368 
3. Herculase II Fusion DNA Polymerase Kit, Agilent, # 600679 369 
4. Q5 High-Fidelity DNA Polymerase, NEB, # M0491S 370 
5. dNTP Set, Thermo Fisher Scientific, # R0181 371 
6. Gene specific primers, e.g. MWG-Biotech 372 
7. Fluorescence labeled gene specific primers, e.g. MWG-Biotech 373 
8. Restriction enzymes, NEB 374 
9. Thermocycler, e.g. Eppendorf 375 
10. Agarose gel electrophoresis (setup and consumables) 376 
 377 
 378 
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3.  Methods 379 
 380 
3.1 Cloning of sgRNAs 381 
This protocol recommends the usage of either plasmid pU6-(BbsI)sgRNA_CAG-Cas9-382 
venus-bpA or pU6-(BbsI)sgRNA_CAG-Cas9_EF1-TagRFP (Workflow A), encoding for 383 
sgRNA and Cas9 and a fluorescent Venus or RFP reporter, or usage of pU6-384 
(BbsI)sgRNA_CAG-venus-bpA, carrying a sgRNA-cassette and a fluorescent reporter only 385 
(Workflow B). These vectors allow expression of the sgRNA by the human U6-promoter. This 386 
promoter requires a “G” base at the transcription start site. Hence, it is recommended using 387 
CRISPR/Cas9 target sites starting with a “G”. Otherwise an additional “G” should be added 388 
at the start of the sgRNA sequence.  It should be noted that wildtype Cas9 is amenable to 389 
the inclusion of an extra “G” but other RNA guided nucleases are not (Cas9-HF/eCas9). All 390 
three above mentioned plasmids together with their maps and sequences are deposited at 391 
Addgene (www.addgene.org) which also provides a wide range of other vector systems for 392 
Cas9 expression and sgRNA cloning. 393 
 394 
 395 
3.1.1 Cloning of a single sgRNA 396 
Annealing of sgRNA oligos 397 
The sgRNA oligos can be cloned into the above mentioned vectors by BbsI restriction 398 
enzyme overhangs, with N1-N20 as the selected Cas9 target sequence: 399 
 400 
sgRNA-oligo-F 5’ –CACC(G)N1NNNNNNNNNNNNNNNNNNN20 –3’ 401 
sgRNA-oligo-R 5’ –AAACNNNNNNNNNNNNNNNNNNNN(C) –3’ 402 
 403 
1.  Resuspend oligos at 1 µg/µl in 1x TE-buffer. 404 
2. Combine in a microcentrifuge tube  405 
- 1 µl oligo F (1 µg/µl) 406 
- 1 µl oligo R (1 µg/µl) 407 
- 98 µl 1x TE-buffer 408 
3. Incubate 5 min at 98 °C in a heat block. 409 
4. Switch off the heat block and cool down slowly to RT for 1-2 h. 410 
5. Put the annealed oligos on ice or store at -20 °C.  411 
 412 
Digestion of sgRNA expression vector 413 
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1. Set up digestion reaction as following: 414 
- X µl of the above mentioned vectors (5 µg) 415 
- 2.5 µl BbsI (store at -80 °C) 416 
- 10 µl NEB2 buffer 417 
- Fill up to 100 µl with nuclease free water 418 
2. Incubate at 37°C for 1 h. 419 
3. Inactivate the restriction enzyme for 20 min at 65 °C.  420 
4. Load the digested vector on a 0.9% agarose gel and extract the linearized vector 421 
using a DNA gel extraction kit. Expected fragment sizes are: pU6-422 
(BbsI)sgRNA_CAG-Cas9-venus-bpA  – 10.1 kb; pU6-(BbsI)sgRNA_CAG-Cas9-423 
bpA_EF1-RFP – 11.6 kb; pU6-(BbsI)sgRNA_CAG-venus-bpA – 6.0 kb. 424 
 425 
Ligation of sgRNA oligos 426 
1. Set up ligation in a microcentrifuge tube  427 
- X µl linearized vectors (100 ng) 428 
- 1.5 µl annealed oligos (1 µg/µl each) 429 
- 1.5 µl fresh ligase buffer 430 
- 1 µl T4 DNA Ligase 431 
- Fill up to 15 µl with nuclease free water and incubate O/N at 16 °C. 432 
Transformation 433 
1. Thaw chemically competent E. coli on ice slowly. 434 
2. Pipet the transformation reaction on ice 435 
- 50 µl chemically competent DH5 alpha E. coli 436 
- 5 µl of the ligation mix. 437 
3. Incubate 30 min on ice. 438 
4. Perform the heat shock in a water bath at 42 °C for 90 sec. 439 
5. Incubate 3 min on ice. 440 
6. Add 1 ml LB medium w/o antibiotics and incubate 30 min at 37°C at 200 rpm.  441 
7. Plate the transformation on LB-Agar plates 50 µg/ml carbenicillin or ampicillin and 442 
incubate O/N at 37°C.  443 
The next day pick up to five colonies and inoculate 5 mL LB medium containing 50 µg/ml 444 
carbenicillin or ampicillin. Incubate O/N at 37 °C at 200 rpm. Perform plasmid mini 445 
preparations and subject for Sanger sequencing to verify the correct sequence using primer 446 
hU6-For: GAGGGCCTATTTCCCATG.  447 
Optional: Redigestion of the ligated plasmid using the enzyme BbsI improves the cloning 448 
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efficacy.  449 
 450 
 451 
3.1.2 Cloning of multiple sgRNAs  452 
To clone multiple sgRNA expression cassettes in pU6-(BbsI)sgRNA_CAG-venus-bpA via 453 
Gibson assembly, the individual sgRNAs have to be cloned separately beforehand  as 454 
previously described in section 3.1.1. These single sgRNA plasmids serve as template for 455 
amplifying a specific sgRNA cassettes including overlapping ends for Gibson assembly. The 456 
following protocol enables to assemble two or three sgRNA expression cassettes in one 457 
vector. If it is intended to clone more than three sgRNAs in one vector primer pairs have to 458 
be designed with appropriate assembly overhangs, according to manufacturer guidelines.  459 
Following primers can be used for cloning: 460 
 461 
Gibson-pU6-A_F CAGGAAACAGCTATGACCATGAGGGCCCCCTTCACCGAGGGCCTATTTC 462 
Gibson-pU6-A_R CCGATGGCCAGGCCGATGCTGTGATCAAAAAAAGCACCGACTCGG 463 
 464 
Gibson-pU6-B_F ACAGCATCGGCCTGGCCATCGGGCCCCCTTCACCGAGGGCCTATTTC 465 
Gibson-pU6-B_R CTTGGCCATCTCGTTGCTGAAGATCAAAAAAAGCACCGACTCGG 466 
 467 
Gibson-pU6-C_F TTCAGCAACGAGATGGCCAAGGCCCCCTTCACCGAGGGCCTATTTC 468 
Gibson-pU6-C_R GTCAATAATCAATGTCGAATCCGGGATCAAAAAAAGCACCGACTCGG 469 
 470 
Use primer combinations A_F/A_R; B_F/B_R and C_F/C_R if three cassettes are desired to 471 
be cloned and combinations A_F/A_R and B_F/C_R if it is desired to clone two sgRNA 472 
cassettes.  473 
 474 
Amplification of guide RNA cassettes with overhangs for assembly 475 
1. Set up PCR reaction in 50 µl reaction volume: 476 
- 5 – 20 ng plasmid DNA 477 
- 0.25 µM primer (each) 478 
- 250 µM dNTPs (each) 479 
- 0.5 µl Herculase II 480 
- Fill up to 50 µl with nuclease free water.  481 
2. Carry out the PCR reaction with following conditions: 98 °C, 2 min; [98 °C, 30 sec; 482 
55°C, 30 sec; 72 °C, 30 sec] x30 cycles; 72 °C 2 min.  483 
3. Load the PCR products on a 1% agarose gel and purify the 412 bp fragment using a 484 
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DNA gel extraction kit. 485 
 486 
Digestion of sgRNA expression vector 487 
1. Set up digestion reaction as following: 488 
- X µl plasmid DNA, pU6-(BbsI)sgRNA_CAG-venus-bpA (5 µg) 489 
- 2.5 µl AscI restriction enzyme 490 
- 10 µl CutSmart buffer 491 
- Fill up to 100 µl with nuclease-free water 492 
2. Incubate at 37°C for 1 h. 493 
3. Inactivate the restriction enzyme for 20 min at 65 °C.  494 
4. Load the digested vector on a 0.9% agarose gel and extract the linearized vector 495 
backbone using a DNA gel extraction kit. Expected fragment sizes are: 5586 bp for 496 
the vector backbone and 383 bp for the empty sgRNA cassette.  497 
 498 
Gibson assembly reaction  499 
1. Set up assembly reaction as following: 500 
- 200 ng AscI linearized plasmid DNA, pU6-(BbsI)sgRNA_CAG-venus-bpA  501 
- 30 ng PCR product (each) 502 
- 10 µl Gibson assembly master mix (2x) 503 
- Fill up to 20 µl with nuclease-free water 504 
2.  Incubate at 50 °C for 1 h. 505 
3. Perform transformation as described in section 3.1.1 506 
4. Conduct test digests with NdeI on five to ten plasmid mini preparations. The expected 507 
fragment sizes are: for assembly of two sgRNA expression cassettes 5515 bp; 436 508 
bp and 391 bp and for three sgRNA expression cassettes 5515 bp; 436 bp¸391 bp 509 
and 390 bp. Subject two plasmids with the correct digestion pattern for Sanger 510 
sequencing using following primers:  511 
pU6-(BbsI)sgRNAseqF: TTGTGTGGAATTGTGAGCGG 512 
 pU6-(BbsI)sgRNAseqR: GGCTATGAACTAATGACCCCG 513 
 514 
Optional: To improve the transformation efficacy perform a clean-up of the assembled 515 
reaction using a PCR purification kit, prior to transformation. 516 
 517 
 518 
3.2 Feeder-free hiPSC culture conditions 519 
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Cultivation of high-quality human iPS cells requires optimal and aseptic conditions. 520 
The cultures should be free of viral, mycoplasmic and bacterial contaminations and have a 521 
normal karyotype. It is recommended to cultivate human iPSCs in antibiotic-free media to 522 
avoid the overlooking of mycoplasma infections. Therefore, it is worth to emphasize the 523 
importance of aseptic culture conditions. The optimal growth conditions for human iPS cells 524 
are in a humidified, hypoxic incubator equipped with a HEPA-filter at 37°C with 1-5 % O2 and 525 
5 % CO2. Feeder-free iPS cell culturing requires special culture media and culture plate 526 
coatings. Since different hiPSC lines may demand different conditions, it is recommended to 527 
test multiple commercially available hiPSC media and coatings. Pluripotent stem cells, such 528 
as hiPSCs have a doubling time of 18-20 h and should therefore be passaged every 3 to 4 529 
days. If the culture becomes over-confluent, iPS cells tend to grow as multi-layers and 530 
spontaneously differentiate. Induced pluripotent stem cells are sensitive to environmental 531 
changes, thus monitor the culture on a daily base. To keep the culture in high-quality 532 
condition, it is recommended to reduce the time of cells being outside the incubator to a 533 
minimum. When exposed to stress by e.g. dissociating to single cells or transfection, iPS 534 
cells induce apoptosis by activation of the ROCK (Rho-associated protein kinase) pathway. 535 
To avoid cell death a ROCK inhibitor (Y-27632) should be added to the culture medium 536 
overnight, when the cells are transfected or passaged. The addition of ROCK inhibitor 537 
changes the morphology of the iPSCs, cells will grow extensions and look fibroblast-like. 538 
These changes are reversible and will vanish when Y-27532 is removed. 539 
     540 
The following protocol is optimized for the healthy donor-derived hiPS cell lines: MIRJT7i-541 
mND2-0 (WiCell), Kolf-2 (HipSci), XM001 (Helmholtz Center Munich) and BCRT#1 (Berlin-542 
Brandenburg Center for Regenerative Therapies). 543 
 544 
3.2.1 General feeder-free human iPSC culture  545 
1. Culture hiPSCs on cell culture plates pre-coated with an appropriate coating (e.g. 546 
Matrigel Matrix, Fisher Scientific or truncated rhVitronectin (VTN-N), Life 547 
Technologies). 548 
2. Culture in appropriate medium (e.g. Essential 8 Medium). 549 
3. Change medium on a daily basis, when using Essential 8. 550 
4. Passage the cells when they reach 60 % to 80 % confluency. 551 
5. hiPS cells can be passaged either using dissociation buffer as patches for 552 
maintenance or using Accutase as single cells, when transfection or FACS 553 
enrichment is desired. 554 
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 555 
Nevertheless, even properly handled hiPSC cultures might start to expose differentiated 556 
cells. Such cells appear as fibroblast-like outgrowths at the edge of hiPSC colonies. 557 
Contamination by differentiated cells can be eliminated by selectively transferring the hiPSC 558 
culture to a new pre-coated cell culture plate using ReLeSR according to the manufacturer's 559 
manual. 560 
 561 
3.2.2 Passaging hiPSC using dissociation buffer 562 
1. Remove medium and wash the cells once with DPBS. 563 
2. Add 0.5 ml dissociation buffer (see 2.3.13) per well of a 6-well plate and incubate for 564 
3-5 min at 37 °C.  565 
3. When colonies begin to detach at the edges, remove the dissociation buffer and add 566 
0.5 ml of Essential 8 medium. 567 
4. Detach cells by tapping the plate and gently flush them off with medium using a 568 
pipette. 569 
5. Pipet carefully 2-3 times to break bigger cell clumps into small ones. 570 
6. Resuspend the cells in appropriate volume of medium (optional: including 10 µM 571 
ROCK inhibitor) and plate the cells on cell culture plate with an appropriate coating.  572 
7. Change medium the following day. 573 
 574 
3.2.3 Passaging hiPSC using Accutase 575 
1. Remove medium and wash the cells once with DPBS. 576 
2. Add 0.5 ml Accutase per well of a 6-well plate and incubate for 3-5 min at 37 °C.  577 
3. When colonies begin to detach and fall apart, add 2 ml Essential 8 Medium 578 
supplemented with 10 µM with ROCK inhibitor. 579 
4. Pipet carefully up and down to break cell patches to single cells and spin down at 300 580 
g for 4 min.  581 
5. Resuspend in appropriate volume of medium including 10 µM Y-27632 and plate the 582 
cells on cell culture plates with appropriate coating.  583 
6. Change medium the following day. 584 
 585 
3.2.4 Cryopreservation of hiPSC 586 
1. Detach hiPS cells using dissociation buffer as previously described. 587 
2. Very carefully resuspend the colonies in 0.75 ml of Essential 8 medium per well, 588 
leaving the colonies as large as possible.  589 
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3. Add 0.75 ml cold Essential 8 medium supplemented with 20 % DMSO drop by drop to 590 
the freezing vial and swirl gently (final DMSO concentration: 10%). 591 
4. Distribute the cell suspension to three cryopreservation tubes, each with 500 µl. 592 
5. Put cryovials into a freezing container (e.g. Mr. Frosty, Nalgene) and freeze at -80 °C 593 
for 24 h before shifting the vials to liquid nitrogen for long term storage. 594 
Optional: Alternatively to growth medium supplemented with 10% DMSO, BamBanker can be 595 
used as cryopreservation medium. The usage of BamBanker increases the viability.  596 
 597 
3.2.5 Thawing hiPSC 598 
1. Remove the cryovial containing the frozen cells from liquid nitrogen and transport 599 
them to the cell culture lab on dry ice.  600 
2. Immediately place it into a 37°C water bath. 601 
3. Thaw cells by gently swirling the vial in the water bath until there is only a small piece 602 
of ice left. 603 
4. Wipe the outside of the tube with 70 % ethanol quickly and transfer the vial to the 604 
laminar flow hood.  605 
5. Add 1 ml pre-warmed Essential 8 medium in a dropwise manner to the cells and 606 
incubate for 1 min. 607 
6. Transfer the thawed cells to a 15 ml centrifugation tube and add another 4 ml 608 
Essential 8 medium. 609 
7. Centrifuge the cell suspension at 200 g for 4 min.   610 
8. Aspirate the supernatant without disturbing the cell pellet. 611 
9. Gently resuspend the cells in Essential 8 medium. 612 
10. Plate the cells on cell culture 6-well plates pre-coated with an appropriate coating in 613 
Essential 8 medium supplemented with 10 µM Y-27632.  Depending on the density 614 
the cells were frozen at, we recommend to plate the cells at different dilutions, 1:2 615 
and 1:10. 616 
11. Change the medium the following day to Essential 8 medium without Y-27632. 617 
 618 
3.3 Transfection of CRISPR/Cas9 constructs into hiPS cells 619 
We suggest using unmodified hiPSC lines for editing of a single target gene (Workflow 620 
A) or using hiPS cell lines expressing Cas9 under a strong doxycycline inducible promoter if 621 
one intends to modify multiple genes simultaneously (Workflow B). In our laboratory we 622 
generated several different hiPS cell lines carrying an inducible Cas9 in the safe harbor locus 623 
AAVS1, based on Gonzales et al. [19] (cell lines available upon request). Instead of using the 624 
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M2rtTA transactivator we used the TRE-3G Tet-on transactivator that drives a stronger 625 
expression upon doxycycline induction (Fig. 2C). The inducible Cas9 system is a versatile 626 
tool to generate complex genotypes in a one-step experiment (Fig. 2B). Since the cells are 627 
already equipped with Cas9, smaller plasmids carrying only the sgRNAs and a 628 
reporter/selector have to be transfected transiently, which improves the transfection 629 
efficiency (Fig. 5). 630 
An efficient transfection of a CRISPR nuclease and the sgRNA is indispensable for 631 
successful genome editing. The choice of a certain transfection method depends upon its 632 
efficacy in a hiPS cell line of interest as well as on the viability of the cell line, when exposed 633 
to the transfection method. Generally small vectors < 8 kb can be more efficiently transfected 634 
and induce less cell death than large vectors >8 kb (Fig. 5A and B). However, where some 635 
lines can be efficiently transfected by reagent or chemical-based transfection methods such 636 
as Lipofectamine 3000, others respond well to electroporation. Thus, transfection conditions 637 
have to be optimized for different iPS cell lines as shown in Figure 5. 638 
 639 
- Figure 5 - 640 
 641 
Here we describe three different transfection methods generally used for 642 
CRISPR/Cas9-based gene editing. These methods are based on transient transfection of 643 
plasmids expressing Cas9 and/ or sgRNAs. Depending upon the nature of the planned 644 
experiment, multiple sgRNAs can be transfected simultaneously to achieve multiplex gene 645 
editing. To facilitate generation of gene edited clones we recommend to use either a 646 
fluorescent marker if FACS sorting is feasible or selection markers like puromycin or 647 
hygromycin on the plasmid encoding for Cas9 and sgRNA to enrich transfected cells.  648 
This protocol is based on hiPS cells grown in feeder-free conditions in Essential 8 culture 649 
media in a 6-well cell culture plate. 650 
 651 
 652 
3.3.1 Reagent-based transient transfection using Lipofectamine 3000  653 
 654 
1. Prepare plasmid DNA at a concentration of 0.5-1 µg/µl in deionized water or TE 655 
buffer. The DNA used for transfection should be of high quality as poor quality of DNA 656 
might decrease the efficacy of transfection.  657 
2. One day prior to transfection dissociate the cells using Accutase and seed 5x104 – 658 
1x105 cells per well of a pre-coated 6-well plate as single cells or in small clumps. 659 
22 
 
Cultivate the cells in fresh medium containing 10 µM Y-27632 overnight.  660 
3. Change the medium ahead of transfection.  661 
4. Dilute depending on the size of the plasmid between 1 µg and 2.5 µg DNA in 125 µl 662 
of Opti-MEM reduced serum medium in tube labeled as A. Add 3.75 µl of p3000 663 
reagent and mix well. Dilute 5 µl Lipofectamine 3000 reagent in 125 µl of Opti-MEM 664 
reduced serum medium in tube B. Diluted Lipofectamine 3000 should be used within 665 
15 minutes. Longer times can result in decreased transfection efficacy. 666 
5. Add the content of tube A to tube B, mix well by pipetting and incubate at room 667 
temperature for 5 minutes.  668 
6. Add the DNA-lipid complex to one well of a 6-well plate in a dropwise manner and 669 
gently rock the plate to ensure its distribution over the whole well. Some cell lines are 670 
sensitive to Lipofectamine 3000. 671 
Optional: The addition of 5 µM Y-27632 to the culture medium for 24 h increases 672 
viability.  673 
7. Change medium on the following day. When iPS cells harboring a doxycycline 674 
inducible Cas9 were used, feed the cells for 48 h with medium supplemented with 1 675 
µg/ml doxycycline.  676 
8. Keep in culture until FACS sorting (section 3.4) or extraction of total DNA for analysis 677 
of bulk population (see section 3.5 for the method of choice for analysis). 678 
9.  679 
 680 
3.3.2 Electroporation-based transient transfection using the Neon system 681 
The following protocol describes the electroporation procedure using the 100 µl Neon 682 
Transfection kit, aiming for a 6-well plate format. The DNA used should be of high quality to 683 
achieve the optimal results. 684 
 685 
1. Prepare highly concentrated plasmid DNA (1-5 µg/µl) in deionized water or TE buffer. 686 
The amount of plasmid DNA should not exceed 10% of the total volume of 687 
resuspension buffer.  688 
2. Coat a 6-well plate with appropriate coating. 689 
3. Pre-warm Essential 8 medium containing 10 µM Y-27632. 690 
4. Change the medium ahead of transfection. 691 
5. Dissociate the cells using Accutase and spin down for 4 min at 300 g.  692 
6. Wash the cell pellet once with PBS. 693 
7. Dilute 5.5 µg total plasmid DNA in 110 µl buffer R (part of Neon transfection kit) in a 694 
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microcentrifuge tube.  695 
8. Resuspend 6x105 cells in 110 µl buffer R containing the DNA. Care should be taken 696 
while resuspending for no air bubbles will be formed. Presence of air bubbles will lead 697 
to unsuccessful electroporation. 698 
9. Fill 3 ml of electrolytic buffer E2 (provided with the Neon kit) into a Neon tube and 699 
insert it into the pipetting station. A single Neon tube can be used up to 10 times. 700 
10. Insert a 100 µl Neon tip into the Neon pipette. Make sure that the tip is adjusted 701 
correctly before pipetting the cell/ DNA mix. 702 
11. Load the appropriate Neon program (it is advised to optimize settings for each cell 703 
line using a fluorescent plasmid). The electroporation parameters we generally use 704 
are 1 pulse at 1300 V and a duration of 30 ms. 705 
12. Press start and wait until the procedure is complete. A single Neon tip can be used 706 
twice with the same plasmid/cell line. 707 
13. Transfer the electroporated cells to a microcentrifuge tube containing 500 µL medium 708 
supplemented with 10 µM Y-27632 and pellet at 300 g for 4 min. 709 
14. Resuspend the cells in 600 µL fresh medium supplemented with Y-27632. Plate 100 710 
µL cell suspension into one well of a pre-coated 6-well plate containing 2 ml medium 711 
supplemented with 10 µM Y-27632. 712 
15. Rock the plate gently and incubate the cells. 713 
16. Change medium the following day. When iPS cells harboring a doxycycline inducible 714 
Cas9 were used, feed the cells for 48 h with medium supplement with 1 µg/mL 715 
doxycycline. 716 
Optional: The addition of 5 µM Y-27632 to the culture medium for 24h on the day 717 
after transfection improves viability. 718 
17. Keep in culture until FACS sorting (section 3.4) or extraction of total DNA for analysis 719 
of bulk population (section 3.5). 720 
 721 
3.3.3 Electroporation-based transient transfection using the Gene Pulser system 722 
1. Prepare highly concentrated plasmid DNA (1-5 µg/µl) in deionized water or TE buffer.  723 
2. Change the medium ahead of transfection. 724 
3. Coat a 6-well plate with appropriate coating. 725 
4. Pre-warm Essential 8 medium containing 10 µM Y-27632. 726 
5. Pre-chill a 0.4 cm electroporation cuvette. 727 
6. Dilute the appropriate amount of plasmid DNA (20-40 µg per plasmid, if multiple 728 
plasmids are transfected we recommend to use up to 100 µg DNA) in 850 µl DPBS 729 
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and chill on ice. 730 
7. Dissociate the cells using Accutase and spin down for 4 min at 300 g.  731 
8. Wash the cells once with DPBS, take an aliquot for counting and pellet again at 300 g 732 
for 4 min. 733 
9. Resuspend at16x106 cells/ ml in ice-cold DNA/ PBS dilution and carefully transfer 800 734 
µl of it to the electroporation cuvette containing the DNA, avoid air bubble formation. 735 
10. Incubate on ice for 5 minutes and proceed with electroporation. We generally use 736 
following parameters: single pulse at 300 V and 500 µF, the time constant should be 737 
between 10 ms and 15 ms. It is advised to optimize settings for each cell line using a 738 
fluorescent plasmid. 739 
11. Immediately after the pulse add 500 µl of pre-warmed culture medium supplemented 740 
with ROCK inhibitor Y-27632 to the cells. 741 
12. Transfer the cells to a microcentrifuge tube and pellet them by centrifugation. 742 
13. Resuspend the cells in 600 µl fresh medium containing Y-27632 and plate 100 µl cell 743 
suspension into one well of a pre-coated 6-well plate containing 2 ml medium 744 
supplemented with 10 µM Y-27632. 745 
14. Rock the plate gently and incubate the cells.  746 
15. Change medium the following day. When hiPS cells harboring a doxycycline inducible 747 
Cas9 were used, feed the cells for 48 h with medium supplement with 1 µg/ml 748 
doxycycline. 749 
Optional: The addition of 5 µM Y-27632 to the culture medium for 24 h improves 750 
viability. 751 
16. Keep in culture until FACS sorting (section 3.4) or extraction of total DNA for analysis 752 
of bulk population (see section 3.5). 753 
 754 
3.4 FACS enrichment and clonal isolation hiPS cells  755 
Selecting cells that were successfully transfected improves the rate of gene editing cells. In 756 
this protocol, we describe the enrichment of transfected cells by FACS (Fig. 6). If there is no 757 
opportunity to utilize FACS, other selection methods e.g. using antibiotics like puromycin or 758 
hygromycin can be applied. Cultivating hiPS cells in 50 % conditioned medium dramatically 759 
increases cell survival of the FACS process [47]. We have observed that the usage of 760 
conditioned medium increases the viability of single seeded iPS cells in low density and 761 
prevents the cells from spontaneous differentiation. Nevertheless, the procedure of FACS 762 
enrichment might induce cell stress therefore we suggest processing the cells as fast as 763 
possible. To avoid contaminations during FACS we suggest using penicillin and streptomycin 764 
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as well as gentamicin. The dissociated cells should not be kept on ice for longer than 45 765 
minutes.  766 
 767 
- Figure 6 - 768 
 769 
3.4.1 FACS enrichment of transfected hiPSC 770 
1. Prepare post-FACS medium: 50 % fresh Essential 8 medium, 50 % conditioned 771 
Essential 8  medium (medium that was conditioned for 24 h on hiPS cells with 50-80 772 
% confluency of the same line and filtered through a 0.45 µm PTFE membrane filter) 773 
supplemented with 10 µM Rock inhibitor Y-27632 , RevitaCell Supplement (1X), 774 
Pen/Strep (1X), and Gentamicin (1X). 775 
2. Coat a 6-well plate with appropriate coating. 776 
3. For each FACS sample, prepare 1.5 ml microcentrifuge tube with 1 ml post-FACS 777 
medium and keep on ice. 778 
4. Pre-warm Essential 8 medium containing 10 µM Y-27632, Pen/Strep (1X), and 779 
Gentamicin (1X). 780 
5. Dissociate cells using Accutase and spin down for 4 min at 300 g.  781 
6. Resuspend the cells thoroughly by pipetting the cells 5-10 times to achieve a single 782 
cell suspension. We suggest resuspension in 200 to 300 µl medium per well of a 6-783 
well plate at 70 % - 80 % confluency 784 
7. Strain through a strainer cap with a mesh size of 35 µm into a FACS tube.  785 
8. Put cells on ice and proceed with FACS immediately. 786 
9. Depending on the nature of your experiment and the chosen fluorophore, sort for your 787 
desired cell population directly into a cooled 1.5 ml microcentrifuge tube containing 1 788 
ml of post-FACS medium. 789 
10. Seed 300-500 cells per well in 2 ml post-FACS medium in a 6-well format as quickly 790 
as possible after sorting. Prepare several wells for each sample. 791 
11. Make sure single cells are evenly distributed throughout the well to ensure 792 
emergence of single cell derived colonies. 793 
12. Additionally, seed the remaining cells at a higher density on a separate well. This well 794 
can be used after expansion for gDNA extraction from the sorted bulk population and 795 
subsequent PCR based genotyping to determine the rough gene targeting efficacy for 796 
example by RFLP. This can be very helpful to determine the number of single clones 797 
that need to be analyzed for the specific gene targeting event. 798 
In case of low gene targeting efficacy, two rounds of transfection and sorting can be of 799 
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advantage to enrich for gene edited single clones. Therefore, seed all positive cells 800 
coming out of the first sort. Once the cells have recovered, and have reached an 801 
appropriate confluency, transfect them again, followed by a second sorting step. 802 
 803 
3.4.2 Clonal isolation of hiPSCs 804 
1. Culture the sorted cells for 5 days in 50 % conditioned and 50 % fresh medium until 805 
small colonies emerge. Change medium daily. 806 
Optional: The addition of 5 µM Rock inhibitor Y-27632 for 1 to 2 days to the medium 807 
(50 % conditioned and 50 % fresh medium) improves viability of single cell derived 808 
clones. 809 
2. At day 6 switch to regular Essential 8 medium and continue with daily feeding. 810 
3. Closely monitor the growth of the single cell derived colonies to exclude the possibility 811 
that neighboring colonies fuse together. This can be done by circling neighboring 812 
colonies on the bottom side of the well with a marker pen. 813 
4. After approximately 7 to 10 days colonies are large enough for manual picking. 814 
5. Gently scratch the colonies into smaller, checkered patches either using a small 815 
needle or using a 10 µl pipette tip utilizing a stereo microscope in a sterile 816 
environment. 817 
6. Transfer the patches of one clone to one well of a pre-coated 12-well plate containing 818 
pre-warmed medium supplemented with 10 µM Y-27632.  819 
7. Gently resuspend the cell patches by pipetting up and down with a 1000 µl tip. After a 820 
few days colonies may need to be dissociated with EDTA within the plate to break 821 
apart the large colony and avoid differentiation of the cells. 822 
8. As soon as the cells build larger colonies, split each clone on 2 separate wells in 823 
either 12- or 6-well format in a 20 % to 80 % ratio. Use one plate (80 %) for further 824 
expansion and subsequent gDNA extraction, followed by PCR based genotyping to 825 
detect CRISPR/Cas9 edited clones. 826 
9. Meanwhile, you can freeze the second plate as a back-up (20 %). It is recommended 827 
to use the BamBanker cryopreservation solution instead of 10 % DMSO when 828 
freezing iPSCs in a multiwell plate instead of cryovials. 829 
10. Aspirate the medium and cover the wells with dissociation buffer. Incubate the plate 830 
for 3-5 min at 37 °C. Aspirate the Dissociation reagent and add 0.3-0.5 ml of 831 
BamBanker cryopreservation solution. Gently dissociate the colonies by repeated 832 
pipetting. Seal the plate with Parafilm and store the plate at -80 °C in a Styrofoam box 833 
until further use. 834 
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11. In most cases, cryo-preservation of the single cell derived clones after further 835 
expansion is recommended as a back-up (section 3.2.4).  836 
 837 
3.5 Analysis techniques of CRISPR/Cas9 induced modifications 838 
There is a variety of methods to analyze genome modifications. Table 1 summarizes the 839 
most common methods for analyzing indels or point mutations. Most of them are based on 840 
PCR amplification of the targeted region, and in such cases optimization of the PCR 841 
reactions is a prerequisite for clear analysis results. For successful PCR we recommend 842 
using a high fidelity polymerase such as Herculase II (Agilent) or Q5 (NEB). We suggest to 843 
use fragment analysis or Sanger sequencing followed by TIDE [48] analysis for indel 844 
detection in clonal derived cells. To detect indels in bulk populations we use deep 845 
sequencing of fragments. For evaluation of inserted point mutations we recommend RFLP to 846 
pre-screen bulk populations or single cell derived clones and Sanger or deep sequencing for 847 
verifying the correct integration of the targeting donor.  848 
 849 
- Table 1 - 850 
 851 
3.5.1 PCR design 852 
Depending on the analysis assay the requirements on the PCR reaction differ mainly in the 853 
size of the PCR product. The major requirement for all analysis methods is a specific 854 
amplification of the desired genomic locus. Therefore while designing the primers 855 
heterozygous mutations or SNPs as well as repetitive sequences should be avoided. When 856 
using Sanger sequencing followed by TIDE analysis the smallest recommended product 857 
length is 250 bp. To guarantee adequate sequence decomposition, the sgRNA targeting site 858 
should be 150 bp – 400 bp distant from the sequencing primer binding site. For fragment 859 
analysis, amplicon sizes ranging from 200-650 bp can be used to ensure a precise resolution 860 
up to a single base. However, the smaller the amplicons are the higher the resolution will be. 861 
For the RFLP assay the PCR should be designed in a way that product length should be in a 862 
range of 400-1200 bp and the sgRNA target site is off-set of the amplicon center.  863 
 864 
3.5.2 PCR reaction and purification 865 
Genomic DNA (gDNA) can be extracted from hiPS cells of either a semi-confluent well of a 866 
6-well plate or a confluent well of a 12-well plate with the Wizard (Promega) or other DNA 867 
purification kits. PCR reactions are carried out using 100 ng gDNA in 50 µl with Herculase II 868 
according to manufacturer’s instructions. For Sanger sequencing or fragment analysis the 869 
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PCR products are gel purified using e.g. the Wizard SV Gel and PCR Clean-Up System 870 
(Promega).  871 
 872 
3.5.3 Sanger sequencing  873 
Purified PCR products are prepared for sequencing using 20 pMol of sequencing primer and 874 
60 -150 ng amplicon. The sequencing can be conducted by a commercial provider, e.g. LGC 875 
Genomics.  876 
 877 
3.5.4 TIDE analysis 878 
Tracking of Indels by DEcomposition (TIDE) is a method for quantitative assessment of 879 
genome editing events (https://tide.nki.nl/) [48]. By aligning the sgRNA sequence to the 880 
control sequence TIDE first identifies the expected Cas9 induced double-strand break site. 881 
Based on the peak heights TIDE then analyzes the abundance of aberrant nucleotides over 882 
the length of the sequence. The sequences are then evaluated with a decomposition 883 
algorithm to identify the insertion and deletion mutations in the subjected sequencing file. 884 
Clear sequencing traces are an essential requirement for solid indel detection and 885 
quantification. For the TIDE analysis the sequencing files of mutated and control samples 886 
can be uploaded to the TIDE web tool as .ab1 or .scf files and analyzed with the preset 887 
parameters, except for the indel size range which is reset to 20. 888 
 889 
3.5.5 Fragment analysis 890 
Fragment analysis is a useful tool to evaluate indel formation in single cell derived clones as 891 
well as in cell populations. When loading fluorescent labeled PCR products of the edited 892 
sgRNA target site on a capillary sequencer, amplicons differing in size due to small insertions 893 
or deletions can be separated with accuracy in resolution, depending on the size of the PCR 894 
product. PCR products with a length of up to 650 bp can be separated with a resolution of a 895 
single base. For this approach, fluorescently labeled forward primers (HEX, TET or 6-FAM) 896 
must be used to amplify the region of interest. Subsequently the PCR products are loaded on 897 
an agarose gel, purified using a PCR Clean-Up System (Promega) and 60 - 150 ng of the 898 
purified samples are subjected to analysis (SMB Service GmbH, Berlin, Germany) using LIZ-899 
500 size standard.  900 
 901 
3.5.6 RFLP assay 902 
RFLP assays can be applied to assess indel formation when a restriction enzyme recognition 903 
site is located at the sgRNA targeting sequence, adjacent to the site of DSB, or to screen for 904 
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HDR events when additional restriction sites are inserted in the donor template. The 905 
amplicon size for this assay type should range from 400 bp to 1200 bp whereas the 906 
restriction site should be off-set to the center to facilitate the detection of both restriction 907 
fragments. The PCR products can be digested without further purification steps when 908 
choosing restriction enzymes that are active in the PCR buffer. For the digestion 20 µl PCR 909 
product are combined with 5 units of the selected enzyme, incubated at 37 °C for 1 h and 910 
analyzed on a 1.5 % agarose gel. RFLP analysis can also be combined with fragment 911 
analysis, when using fluorescent labeled primers for amplification. We recommend RFLP 912 
assays to determine the abundance of mutagenesis events in a bulk population, to estimate 913 
the efficacy of a CRISPR/Cas9 experiment and decide how many clones to analyze. 914 
 915 
3.5.7 T7E1 Assay 916 
The T7E1 and Surveyor assays can be used to assess indels and heterozygous point 917 
mutations in single cell derived clones as well as in bulk populations.  Furthermore these 918 
assays are useful tools to test the efficacy of sgRNAs in cell lines like 293 cells. Both assays 919 
are used to detect DNA hetero-duplex formations of PCR amplicons by hybridization of 920 
mutant and wild type sequences or two different mutant sequences. These mutation-921 
sensitive methods fail to detect homo-duplexes e.g. formed by two identical mutant 922 
sequences. Similar to RFLP the amplicon size for T7E1 assay should range from 400 bp to 923 
1200 bp with the CRISPR/Cas9 targeting site off-set to the center of the amplicon. After the 924 
PCR reaction a clean-up step was performed and subsequently the purified fragments were 925 
denatured for 5 min at 98 °C in a heat block and re-annealed by switching of the heat block 926 
for 1-2 h. 200 ng PCR product was digested with 5 units T7E1 (NEB) for 15 min at 37 °C. 927 
After incubation the samples were immediately transferred to ice and supplemented with gel-928 
loading-buffer. The digested fragments were separated on a 1.5 % agarose gel. In our 929 
experience the T7E1 assay often results in nonspecific cleavage products when applied to 930 
iPS cell derived gDNA, hence often needs further optimization steps for different loci. 931 
Therefore we recommend using RFLP (section 3.5.6), Fragment analysis (section 3.5.5) or 932 
TIDE analysis (section 3.5.4). 933 
 934 
 935 
3.5.8 Off-target analysis 936 
Off-target sites of sgRNA are predicted using CRISPOR or CRISPR DESIGNER 937 
(http://crispr.mit.edu/). In general off-target sites with an off-target hit-score > 0.9 are 938 
analyzed by PCR amplification and Sanger sequencing followed by TIDE analysis. In our 939 
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experiments we have observed no off-target effects when designing sgRNAs with the web 940 
tool CRISPOR (http://crispor.tefor.net/) and choosing sgRNAs with specificity scores > 60 941 
and efficacy scores (Fusi score) > 45. Although CRISPR/Cas9 induced off-target effects are 942 
rare in hiPSCs, especially since safer and more accurate sgRNA designing web tools are 943 
available, we encourage the analysis of such potential effects in genome edited cells. In 944 
particular undesired mutations may distort the results when the edited cells are subjected to 945 
a phenotypic comparison with control cells. 946 
 947 
 948 
4. Results 949 
Since expansion and analyzing of genome edited iPSC clones is laborious it is 950 
important to pick and analyze a feasible number of clones. In the following section we 951 
summarize the experience we gathered in our lab to provide guidance in regard to the 952 
number of clones to be analysed. The following data are based on three independent 953 
sgRNAs each targeting an individual native locus. The results we present in section 4.1 are a 954 
summary of experiments where a single guide of each three was used at a time (Workflow 955 
A). In section 4.2 we summarize experiments that implement all three guides at once 956 
(Workflow B). At this point we would like to note that targeting efficacies are, among others, 957 
dependent on the locus of interest, cell lines and the performance of the selected sgRNA. 958 
Therefore, we consider our presented data as a reference point and not as a universal rule.  959 
 960 
4.1 Results obtained with Workflow A 961 
In the course of optimizing gene targeting with transient transfection of Cas9 and 962 
sgRNA (Workflow A) we started with an approach using a plasmid vector carrying Cas9 963 
together with a fluorescent reporter and a separate vector encoding only for a single sgRNA 964 
without any selection gene. The hiPSCs were enriched by FACS for the fluorescent reporter 965 
48h after transfection. With this approach we could enrich only the fraction of cells 966 
transfected with the nuclease but not the guide RNA (Table 2; separate vectors). We 967 
analyzed 176 sorted, single cell  derived clones and obtained only two mutagenized clones 968 
(1 %) where one clone was targeted on both alleles and the second clone on one allele. In 969 
our next approach we transfected hiPSCs with combined vectors, coding for Cas9, the 970 
sgRNA cassette as well as a fluorescent reporter (pU6-(BbsI)sgRNA_CAG-Cas9-venus-bpA 971 
or pU6-(BbsI)sgRNA_CAG-Cas9_EF1-TagRFP). Using this strategy, we could enrich for 972 
cells carrying Cas9 and the guide RNA. By this method we achieved a mutagenesis rate of 973 
17 % in 116 analyzed clones. 70 % of the mutagenized clones were targeted on both alleles 974 
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and 30% only on one (Table 2; combined vector).  975 
Based on these results, we conclude that when it is intended to introduce frameshift 976 
indels in one single gene using transient transfection of Cas9 and sgRNA carrying 977 
fluorescent reporter vectors (Workflow A) followed by FACS enrichment, 24 cell clones is a 978 
reasonable number to obtain 2 to 4 clones with mutations on both alleles. 979 
  980 
- Table 2- 981 
 982 
4.2 Results obtained with Workflow B 983 
In experiments where we used the doxycycline inducible Cas9 system with transient 984 
transfection of fluorescent reporter vectors that express three different sgRNAs (Workflow B) 985 
followed by FACS enrichment, we observed indel mutations in all three loci (Parkin, Dj1, 986 
Pink1) in two out of 24 single cell derived hiPS cell clones (8 %). In one clone we detected 987 
indels in two loci (4 %). None of the analyzed clones were mutated in only one locus. 71 % of 988 
targeted loci were mutated in a bi-allelic manner (Table 3; Single round).  989 
Additionally, we conducted an experiment where we followed Workflow B as described 990 
above, but co-transfected the plasmid pCAG-Trex2-bpA to co-express the end-processing 991 
enzyme Trex2. This experiment resulted in a targeting efficacy of 15 % for triple and 15 % for 992 
double gene mutagenesis (20 clones analyzed in total). None of the analyzed clones were 993 
mutated in a single locus only. Analogous to the previous experiments the majority of the 994 
mutated loci were targeted on both alleles (Table 3; Single round +Trex2).  995 
Finally we could improve the targeting efficacy by repeating the transfection and FACS 996 
sorting procedure a second time (Table 3; Second round). In 15 of in total 57 single cell 997 
derived human iPS cell clones we could detect triple gene mutagenesis (26 %). 7 clones 998 
were targeted on two loci (12 %) and 4 clones carried indels in only one of the targeted loci 999 
(7 %). In accordance with our previous observation the majority of mutations occurred on 1000 
both alleles of a locus.  1001 
-Table 3- 1002 
 1003 
Thus we recommend based on our experience, when it is intended to introduce 1004 
frameshift indels in multiple loci, we suggest using the doxycycline inducible Cas9 system 1005 
with transient transfection of sgRNA carrying fluorescent reporter vectors (Workflow B) 1006 
followed by FACS enrichment. In this case we recommend selecting 36 to 48 clones to have 1007 
a feasible number of multiple edited cell clones. To minimize the number of clones to analyze 1008 
during multiplex gene editing we suggest: a) co-transfection with the plasmid pCAG-Trex2-1009 
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bpA for expression of the end-processing enzyme Trex2 and b) repeating the transfection 1010 
and FACS enriching procedure a second time (sections 3.3 and 3.4). In this regard analyzing 1011 
16 to 24 clones should be adequate to obtain various clones with mutations on both alleles 1012 
for the desired loci (Table 2 and Table 3). If precise genome editing is desired (HDR events) 1013 
we suggest to first determine the efficacy of mutagenesis events in a bulk population e.g. by 1014 
RFLP analysis and depending on that estimate the number of clones to be picked and 1015 
analyzed.  1016 
 1017 
4.3 Quality of targeted human iPSCs 1018 
To monitor, if the CRISPR/Cas9 based gene targeting strategies we describe here have an 1019 
influence on the genetic stability of the targeted cells, we performed SNP analysis based 1020 
virtual karyotyping on edited human iPS cells. The karyotyping was performed with the 1021 
Infinium OmniExpressExome-8 v1.2 BeadChip system that covers over 960,000 common 1022 
SNPs over the human genome. We analyzed two hiPSC clones that were successively 1023 
targeted at the AAVS1 locus to initially create doxycycline inducible Cas9 expressing hiPSCs 1024 
and afterwards at three native loci by two rounds of transfection followed by FACS 1025 
enrichment. Both characterized clones were successfully targeted on both alleles of all three 1026 
loci.  1027 
The SNP based karyotyping revealed no chromosomal aberrations. We detected eight SNPs 1028 
that were absent in an early passage of the parental cell line (data not shown). It is unclear if 1029 
these SNPs emerged during cultivation or are an artifact of the editing process. However, 1030 
pluripotent stem cells are generally considered as genetically unstable and we could 1031 
demonstrate that our editing method does not exacerbate this phenomenon.  1032 
Additionally we analyzed the edited clones for potential mutations at predicted 1033 
CRISPR/Cas9 off-target sites for the individual sgRNAs used here (section 3.5.8). We 1034 
analyzed the most relevant loci with a hit-score > 0.9 regarding to CRISPOR and CRISPR 1035 
DESIGNER. We could not detect any mutation at these sites.  1036 
 1037 
-Figure 7- 1038 
 1039 
We subjected targeted cell clones mentioned above to immunostainings for the 1040 
pluripotency markers OCT4, NANOG, SOX2 and SSEA4 (Figure 7A). We confirmed that 1041 
targeted hiPSCs express common pluripotency markers. 1042 
Furthermore we examined the differentiation potential of hiPS cells, targeted with our 1043 
workflow, to the ectodermal lineage. We performed a neuronal differentiation assay with 1044 
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gene targeted hiPSCs and could demonstrate that these cells are capable to differentiate to 1045 
TUJ1 and TH expressing neuronal cells (Figure 7B). 1046 
 1047 
 1048 
 1049 
5. Conclusion 1050 
Two groundbreaking discoveries of the past decade, human iPS cell technology and gene 1051 
editing using CRISPR/Cas9, provide new opportunities for researchers. Combining both 1052 
allows us to study the function of a gene in a human system in the context of specific 1053 
diseases or even gene therapeutically applications by correcting gene defects in patient 1054 
cells. Using CRISPR/Cas9 in immortalized, fast-cycling cell lines is well established. 1055 
However, using this system in hiPS cells is more challenging due to the sensitive 1056 
requirements of hiPS cells to maintain culture pluripotency. Although generating precise 1057 
knockins via HDR is relatively inefficient, the possibility to use selection markers or 1058 
introducing recognition sites for restriction enzymes in the repair template facilitates 1059 
screening for successfully targeted cells. CRISPR/Cas9 mediated gene disruption by 1060 
introducing indel mutations on the other hand occurs more frequently but screening of clonal 1061 
derived cells is more laborious.  1062 
We describe here a simple and efficient workflow for clonal isolation and screening of 1063 
genome engineered human iPS cells without prior drug selection. Applying this workflow to 1064 
hiPS cell lines equipped with an inducible Cas9 under a strong promoter even enables the 1065 
generation of multiple targeted mutant alleles in a single experiment.  1066 
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Table 1 Summary of analysis methods for genome editing events 1080 
Assay Advantage Disadvantage Application 
Sanger/Tide Quick and simple; 
High accuracy for single 
cell derived clones 
Low accuracy for 
quantification in bulk 
population 
Indel detection in clonal 
derived cells 
Cloning/Sanger High accuracy Very laborious For verification of 
knockins or indels in 
single cell derived clones 
Fragment Analysis Quick and simple; 
 High accuracy for single 
cell derived clones 
Requires special 
equipment/service 
Indel detection in clonal 
derived cells or bulk 
populations 
RFLP Quick and simple; High 
accuracy for single cell 
derived clones 
Low accuracy for 
quantification on bulk 
populations 
Detection of knockins or 
indels in single cell 
derived clones or bulk 
populations 
 
 
 
 
Deep Seq High accuracy Requires special 
equipment/service 
Detection of KI or indels 
in bulk populations and 
single cell derived clones 
T7E1/Surveyor Quick and simple Need thorough 
optimization  
To pre-test sgRNAs in cell 
lines 
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 1089 
Table 2 Results of gene editing in hiPSC using Workflow A 1090 
Approach:        
Workflow A 
Analyzed 
clones 
Single gene 
mutagenesis 
Mono allelic 
events 
Bi alleleic 
events 
Separate vectors:    
Cas9-fluorescent 
reporter and sgRNA 
176 1% 50% 50% 
Combined vector:   
Cas9-sgRNA-
fluorescent reporter  
116 17% 30% 70% 
 1091 
Table 2 Results of gene editing in hiPSC using Workflow B 1092 
Approach:        
Workflow B 
Analyzed 
clones 
Single gene 
mutagenesis 
Double gene 
mutagenesis 
Triple gene 
mutagenesis 
Mono allelic 
events 
Bi alleleic 
events 
Single round:     
inducible Cas9 with 
transient sgRNA-
fluorescent reporter  
24 0% 4% 8% 29% 71% 
Single round +Trex2:    
inducible Cas9 with 
transient sgRNA-
fluorescent reporter 
and mTrex2 
20 0% 15% 15% 33% 67% 
Second round: 
inducible Cas9 with 
transient sgRNA-
fluorescent reporter 
and Trex2 
57 7% 12% 26% 16% 84% 
 1093 
 1094 
 1095 
 1096 
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 1098 
Figure Legends 1099 
Figure 1 The CRISPR/Cas9 nuclease system 1100 
A: Cas9 and sgRNA recognize 20 nt target sequences located upstream of the invariant 3 bp 1101 
NGG PAM sequence (red letters). B: If a target sequence is found upstream of the PAM site, 1102 
each of the RuvC and HNH nuclease domains of Cas9 cut one strand of the target DNA, 1103 
creating a DSB (triangles). C: DSBs in target genes can be either repaired by NHEJ, leading 1104 
to small sequence deletions and gene knockout alleles. Precise sequence modifications 1105 
(Knockin alleles) are introduced by HDR with the homology regions of DNA repair templates, 1106 
either an ssODN or plasmid vector. 1107 
 1108 
 1109 
Figure 2 Strategies for intracellular delivery of components required for CRISPR/Cas9-1110 
mediated gene editing 1111 
A Transfection of an expression vector carrying both a sgRNA cassette and the Cas9 gene 1112 
enables gene editing via DSBs in wildtype cells. B For transgenic cell lines that express 1113 
Cas9 under a doxycycline-inducible promoter, transfection of a vector encoding for sgRNA(s) 1114 
only is sufficient. Successive administration of doxycycline activates Cas9 expression. This 1115 
approach achieves improved efficacy at targeting more than one locus. A reporter gene 1116 
included in either of these strategies allows for the identification of transfected cells. C 1117 
Doxycycline (DOX) dependent expression of Cas9 is provided by a modified AAVS1 locus. 1118 
While the DOX-inducible promoter TREtight and the Cas9 gene are knocked in between the 1119 
first two exons of the PPP1R12C gene (AAVS1 locus) on one allele, the other allele harbors 1120 
the Transactivator gene rtTA3 expressed under the constitutively active CAGGS promoter. 1121 
Presence of DOX mediates binding of rtTA to TREtight, thus activation of Cas9 expression. 1122 
 1123 
Figure 3 HDR efficacy using ssODNs of various architectures 1124 
Cells of the hiPSC line BCRT#1 that heterozygously express EGFP driven by a CAG 1125 
promoter from the AAVS1 locus were co-transfected with an expression vector for both Cas9 1126 
and sgRNA targeting EGFP and various ssODN donor templates. 1127 
A Donor templates were designed to convert EGFP to BFP in case of HDR events, in 1128 
symmetric (sym) [44] or asymmetric (asm) [42] fashion, with and without phosphorothioate 1129 
modification (PTO) [43]. B, C Positively transfected cells were isolated by FACS, based on 1130 
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an RFP fluorophore included in the expression vector. 7 days post transfection HDR/ indel 1131 
frequency was assessed by FACS analysis. Absent fluorescent signal corresponds to indels 1132 
due to disrupted EGFP, BFP+ cells to successful HDR and EGFP+ cells indicate cells not 1133 
undergoing any event. Occurrence of no event was generally low (<4%). HDR frequency of 1134 
both PTO-modified symmetric (6.1%) and asymmetric (4.0) ssODNs were below the efficacy 1135 
of unmodified asymmetric donor templates (12.8%). The highest HDR efficacy was obtained 1136 
using unmodified symmetric ssODNs (20.8%). Experiments were conducted in three 1137 
independent replicates; error bars represent standard error of the mean; significance as per 1138 
Student's t-test: *<0.05, **<0.005, ***<0.0005. 1139 
 1140 
Figure 4 Overview on the workflow for CRISPR/Cas9-mediated generation of a 1141 
transgenic hiPS cell line without drug selection 1142 
Initially, vectors expressing components necessary for CRISPR/Cas9-mediated gene editing, 1143 
i.e. locus specific sgRNA, a fluorescent reporter and optionally Cas9, are required. Available 1144 
combined plasmids provide convenient cloning strategies to include custom sgRNA 1145 
sequences. After transfection of wildtype hiPS cells with these vectors, the included 1146 
fluorescent reporter enables enrichment of successfully transfected cells utilizing FACS. 1147 
Isolated transfected cells are sparsely seeded and expanded for subsequent growth of single 1148 
cell-derived colonies. Appropriate means for analyses allow for the selection of a favored 1149 
colony, which is then established as cell line. 1150 
 1151 
 1152 
Figure 5 Transfection efficacy and cell viability applying various transfection methods 1153 
using vectors of different size and diverse cell lines 1154 
The efficacy of iPS cells transfected with a vector was compared using a small guide-only (4 1155 
kb) and a large combined plasmid (12 kb) applying three methods: Gene Pulser Xcell, Neon 1156 
Transfection System and Lipofectamine 3000. By Gene Pulser Xcell 20 µg of DNA were 1157 
transfected, 5 µg by Neon System and 1.5 µg by Lipofectamine 3000. Efficacy was assessed 1158 
by FACS analysis, counting positively transfected single cells detected by a fluorescent 1159 
reporter included in the vector. 5x105 cells were subjected to Gene Pulser Xcell and Neon 1160 
Transfection System of which 1x105 were subsequently cultured. 1x105 cells were subjected 1161 
to Lipofectamine 3000 transfection. Viability was determined after 48h by FACS based 1162 
quantification of remaining single cells. A Cells of the BCRT#1 iPS cell line were transfected 1163 
at differing efficacy when subjected to Gene Pulser Xcell, Neon Transfection System and 1164 
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Lipofectamine 3000. Transfection efficacy delivering the small guide-only vector amounts to 1165 
41% of all FACS identified single cells using Gene Pulser Xcell, 65% with the Neon System 1166 
and 82% after Lipofectamine 3000 transfection. Delivering the large combined vector yields a 1167 
decreased efficacy regardless the method used. Transfection by Gene Pulser Xcell results in 1168 
10% of successfully transfected single cells, by Neon Transfection System 27% and applying 1169 
Lipofectamine 3000 achieve 59%. B Viability of transfected BCRT#1 iPS cells varies 1170 
depending on the transfection method used as well as on the size of the vector delivered. 1171 
After transfection of the 4 kb vector by Gene Pulser Xcell, Neon System and Lipofectamine 1172 
3000, 6900, 5400 and 6800 remaining single cells were detected, respectively. Subjecting 1173 
the 12 kb vector to transfection yielded 4000, 400 and 2500 live cells. C Efficacy of 1174 
transfecting a 4 kb vector varied between the hiPS cell lines BCRT#1, XM001 and MIRJT7i-1175 
mND2-0. Treatment with Gene Pulser Xcell resulted in 41%, 50% and 25% efficacy, with 1176 
Neon Transfection System 65%, 90% and 38%, with Lipofectamine 3000 82%, 96% and 1177 
90%, respectively. D Cell viability was evaluated after applying different transfection methods 1178 
to BCRT#1, XM001 and MIRJT7i-mND2-0 iPS cell lines. After transfection by Gene Pulser 1179 
Xcell 6800, 5800 and 4200 live cells of the respective cell lines were detected, after Neon 1180 
Transfection System application 5400, 5700 and 2600 remaining single cells were quantified, 1181 
and after Lipofectamine 3000, 6900, 5100 and 100 cells. Experiments were performed in 1182 
triplicates; error bars represent standard error of the mean; significance as per Student's t-1183 
test: *<0.05, **<0.005, ***<0.0005, n.s.=not significant. 1184 
 1185 
 1186 
 1187 
Figure 6 Scheme of the enrichment of hiPS cells transfected for CRISPR/Cas9-1188 
mediated gene editing 1189 
A After transfection of hiPS cells with an appropriate reporter expressing vector, transfected 1190 
cells are identified by FACS based on their fluorescent signal. To increase the yield of 1191 
successfully targeted cells, isolated cells can be expanded and resubjected to transfection 1192 
and FACS enrichment. Representative image of a FACS plot. B1 Single FACS-isolated 1193 
transfected hiPS cells are cultivated sparsely. B2-B5 During the next 5 days following 1194 
seeding a small colony arises from a single cell. B6 After 5 days of culturing a colony forms 1195 
large enough for manual picking and further expansion. Scale bar represents 100 µm. 1196 
 1197 
 1198 
 1199 
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Figure 7 Targeted hiPSCs express pluripotency markers and can differentiate to the 1200 
ectodermal lineage  1201 
A Edited hiPS cells (BCRT#1; edited) and the parental cell line (BCRT#1; parental) were 1202 
subjected to immuno-cytochemistry using antibodies against the pluripotency markers 1203 
SSEA4 (NEB #4755S; 1:500) and NANOG (NEB #4903S; 1:500), OCT4 (NEB #2750S; 1204 
1:500) or SOX2 (NEB #3579S; 1:500), respectively. Nuclei were visualized by DAPI. The 1205 
edited cell line was targeted in two successive steps. Firstly, the AAVS1 locus was targeted 1206 
to express doxycycline inducible Cas9. Subsequently, three native loci were biallelically 1207 
mutated following Workflow B, including two rounds of transfection (and co-transfection of 1208 
Trex2) and FACS enrichment. B The edited cell line (BCRT#1; edited) and a control cell line 1209 
which was targeted at the AAVS1 locus to express Cas9 under a doxycycline inducible 1210 
promotor (BCRT#1; control) were differentiated using the Dopaminergic Neuron 1211 
Differentiation Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. At Day 1212 
38 cells were fixed and subjected to immuno-cytochemistry for the pan-neuronal marker 1213 
TUJ1 (BioLegend #801202; 1:1000) and the dopaminergic neuronal marker TH (Pel-Freez 1214 
#P40101; 1:1000). Nuclei were visualized by DAPI. A and B Cells were cultivated on glass 1215 
cover slips coated with VTN-T (A) or Laminin/Poly-D-Lysin (B). Prior to staining cells were 1216 
fixed for 7 min at RT with 4 % PFA in PBS. Cells were washed thrice with PBS and 1217 
subsequently permeabilized and blocked for 30 min at RT with PBS containing 3 % BSA and 1218 
0.2 % TritonX-100. The cells were washed three more times with PBS and incubated with the 1219 
respective primary antibodies O/N at 4 °C.  The next day, cells were again washed thrice 1220 
with PBS and incubated for 1 h at RT with secondary antibodies (goat-anti rabbit-AF488 and 1221 
goat anti-mouse-AF546, both Thermo Fisher Scientific) and DAPI in PBS supplemented with 1222 
3 % BSA. After final three washes in PBS cells were mounted on glass slides with 1223 
Fluoromount-G (SouthernBiotech). Imaging was performed on a LSM700 confocal 1224 
microscope (Zeiss) with a 20x objective.  1225 
 1226 
 1227 
 1228 
 1229 
 1230 
  1231 
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